bestvideopokerbooks|礼来跌3%，安进减肥新药中期试验获积极数据

Gelonghui May 3| Lillybestvideopokerbooks.US) fell 3% to 733bestvideopokerbooks.27 dollars. on the news frontbestvideopokerbooksMid-term trial of Amgen's new weight-loss drug gets positive databestvideopokerbooksIf the drug is approved, it will compete with Novo Nordisk's Wegovy and Lilly's Zepbound. Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.